Global reach of over 20 years experience in the patient-centered Fabry Registry
Explore the advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community.
This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.
Explore the advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community.
Explore the results and evidence supporting Fabrazyme® and how it was studied through several clinical trials.
Find out more about the safety and tolerability profile for Fabrazyme®.
MAT-XU-2305073 (v1.0) Date of preparation: November 2023